CORRECTION Open Access



Correction: Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer

Chengming Liu^{1,2†}, Lu Yang^{3,4†}, Haiyan Xu^{5†}, Sufei Zheng^{1,2}, Zhanyu Wang^{1,2}, Sihui Wang^{1,2}, Yaning Yang⁴, Shuyang Zhang⁴, Xiaoli Feng⁶, Nan Sun^{1,2*}, Yan Wang^{4*} and Jie He^{1,2*}

Correction: BMC Med 20, 187 (2022) https://doi.org/10.1186/s12916-022-02356-7

After publication of the original article [1], it came to the authors' attention that there is an error in the originally-published version of **Additional file 1: Table S2 and Table S3**. In the univariate and multivariate regression analyses of the association between baseline plasma or tumor tissue IL-6 levels and clinical factors for the prediction of progression-free survival (PFS), the results of smoking history were lost.

The correct version of Additional file 1: Table S2 and Table S3 is published in this erratum.

The original article can be found online at https://doi.org/10.1186/s12916-022-02356-7.

Full list of author information is available at the end of the article

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12916-022-02492-0.

Additional file 1: Table S2. Univariate and multivariate regression analyses of the association between baseline plasma IL-6 levels and clinical factors for the prediction of PFS. **Table S3.** Univariate and multivariate regression analyses of the relationship between baseline tumor tissue IL-6 levels and clinical factors for the prediction of PFS.

Author details

¹Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. ²State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. ³Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing 100191, China. ⁴Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. ⁵Department of Comprehensive Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. ⁶Department of Pathology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Published online: 26 July 2022

Reference

Liu C, Yang L, Xu H, Zheng S, Wang Z, Wang S, et al. Systematic analysis
of IL-6 as a predictive biomarker and desensitizer of immunotherapy
responses in patients with non-small cell lung cancer. BMC Med.
2022;20(1):187. https://doi.org/10.1186/s12916-022-02356-7.



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and you intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativeccommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeccommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

[†]Chengming Liu, Lu Yang and Haiyan Xu contributed equally to this work.

^{*}Correspondence: sunnan@vip.126.com; wangyanyifu@163.com; prof. jiehe@gmail.com

² State Key Laboratory of Molecular Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

⁴ Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China